Recently Approved

March 2008
Pharmaceutical Representative;Mar2008, Vol. 38 Issue 3, p12
The article offers information on drugs that have been approved by the U.S. Food and Drug Administration (FDA). It states that the FDA has approved Nycomed Inc.'s Alvesco, an inhalation aerosol used as maintenance treatment of asthma. The non-nucleoside reverse transcriptase inhibitory Intelence from Tibotec Therapeutics has been approved for use in combination with other antiretroviral agents to treat HIV-1 infection.


Related Articles

  • NEWSLINE.  // Monthly Prescribing Reference;Jul2011, Vol. 27 Issue 7, pA.13 

    A chapter of the book "Monthly Prescribing Reference" is presented. GlaxoSmithKline's Potiga drug has been approved as adjunct treatment for partial-onset seizures in adults. Tibotec Therapeutics' Edurant tablet has been approved for use in combination with other antiretroviral agents in the...

  • Antiretroviral drugs: A Perspective. Kashid, Arun M.; Murumkar, Prashant R.; Dube, Pritam N.; Alkutkar, Pranali G.; Bhatia, Manish S.; Dhawale, Sashikant C. // Journal of Pharmacy Research;2012, Vol. 5 Issue 5, p2837 

    After the invention of first HIV replication inhibitor i.e. Zidovudine, more than fourteen anti HIV drugs have been approved by US FDA for clinical use. Various drug targets along with various inhibitors such as nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse...

  • Etravirine. Kehr, Heather A.; Olin, Jacqueline L.; Love, Bryan L. // Formulary;Mar2008, Vol. 43 Issue 3, p105 

    Etravirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that was approved by FDA on January 18, 2008, for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in antiretroviral treatment-experienced adult patients who have...

  • Tibotec's Intelence Sustains Efficacy in 96-Week Data. Boggs, Jennifer // BioWorld Today;7/21/2009, Vol. 20 Issue 138, p1 

    The article reports that the data from two Phase III trials of the non-nucleoside reverse transcriptase inhibitor Intelence from Tibotec Therapeutics have demonstrated the efficacy of the drug. The data is being used in the review process of the U.S. Food and Drug Administration (FDA) for the...

  • FDA panel OKs Truvada for HIV Prevention. Highleyman, Liz // Bay Area Reporter;5/17/2012, Vol. 42 Issue 20, p1 

    The article reports on the approval of the Food and Drug Administration advisory committee on Truvada as an effective antiretroviral pill to prevent sexual transmission of HIV in the U.S. in 2012.

  • New NNRTI antiviral etravirine gets FDA nod.  // Drug Topics;2/11/2008, Vol. 152 Issue 3, p8 

    The article reports on the U.S. Food and Drug Administration's (FDA) accelerated approval of a non-nucleoside reverse transcriptase inhibitor (NNRTI) from Tibotec. It mentions that the inhibitor is used for the treatment of HIV infection in antiretroviral treatment-experienced adults who show...

  • Biotechs Led in New Drugs for '08.  // BioWorld Today;1/5/2009, Vol. 20 Issue 1, p7 

    The article reveals that the biotechnology industry has surpassed big pharmaceutical firms in achieving U.S. Food and Drug Administration (FDA) approvals of new molecular entities (NME) and new biologics in 2008. 80 new drug applications (NDA) and biologic license applications (BLA) for...

  • Panel: Forest, Nycomed COPD Drug Not Ready for Prime Time. Young, Donna // BioWorld Today;4/8/2010, Vol. 21 Issue 67, p1 

    The article reports that the Pulmonary-Allergy Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) did not give approval to Forest Laboratories Inc. and Nycomed GmbH for their drug against chronic obstructive pulmonary disease (COPD) called Daxas. The panel earlier declared...

  • ANTIRETROVIRAL TOXICITY AND OXIDATIVE STRESS. Elias, Adikwu; Nelson, Brambaifa; Oputiri, Deo; Geoffrey, Oru-Bo Precious // American Journal of Pharmacology & Toxicology;2013, Vol. 8 Issue 4, p187 

    Antiretroviral drugs are used for the treatment of human immunodeficiency virus, they are used as combination regimens to achieve the highest possible benefit, tolerability, compliance and to diminish the risk of resistance development. Reports from preclinical and clinical studies have linked...


Read the Article


Sign out of this library

Other Topics